John Harris, MD, PhD, Chair of Dermatology at UMass Chan Medical School, discusses the impact topical ruxolitinib cream has had on patients with vitiligo. He explains how this treatment has shown exceptional efficacy with limited side effects.
Dr. Del Rosso, JCAD’s Clinical Editor-in-Chief, reviews a poster presented by Volkova et al at the 2024 American Academy of Dermatology annual meeting. The poster presented findings from the TRuE-V long-term extension (LTE) study, which evaluated changes in serum biomarkers in patients with segmental vitiligo who were randomized in the LTE to apply the vehicle or continue using ruxolitinib 1.5% cream after both groups had used ruxolitinib cream in the parent studies....